RLAY$7.63
$7.78
Chart
Performance
Key Stats
AI RLAY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralRelay Therapeutics (RLAY) presents a mixed investment profile. While its core business addresses significant unmet needs in genetic diseases and oncology with a novel platform, current financial performance and market sentiment indicate a neutral outlook. The stock shows potential for long-term upside driven by its pipeline, but near-term volatility and the highly competitive biotech landscape warrant a cautious approach.
Thematic
Relay Therapeutics operates in the high-growth and high-impact areas of precision medicine, targeting oncology and genetic diseases. The company's differentiated scientific approach, focusing on protein motion and allosteric modulation, positions it well within key therapeutic areas experiencing significant investment and innovation.
Fundamental
Relay Therapeutics is a clinical-stage company with significant ongoing R&D expenses, resulting in consistent net losses and negative EPS. While revenue is present, it is minimal and primarily derived from collaborations. The company's balance sheet shows a solid cash position to fund operations, but the lack of profitability and revenue generation from its core products remains a key concern.
Technical
The stock's technical indicators suggest a period of consolidation and potential near-term downward pressure. While it has experienced some recovery over the past month, it remains significantly below its 52-week high, indicating that investor sentiment is mixed. Short-term trading patterns suggest caution.
| Factor | Score |
|---|---|
| Precision Medicine & Targeted Therapies | 90 |
| Oncology Market | 85 |
| Genetic Disease Therapeutics | 80 |
| Biotechnology Innovation & Disruption | 75 |
| Regulatory Landscape (Biotech) | 60 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 20 |
| Balance Sheet Health | 90 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Recent Price Strength
The stock's current price of $3.675 has shown resilience, with a 5-day performance of -0.94% outperforming the broader market's recent movements. Its 1-month performance of 11.36% indicates positive short-term momentum.
Consistent Earnings Surprises
Relay Therapeutics (RLAY) has consistently beaten earnings estimates. For example, Q1 2025 reported EPS of -$0.45 against an estimate of -$0.56 (19.89% surprise), and Q4 2024 reported EPS of -$0.63 against an estimate of -$0.77 (17.92% surprise). This demonstrates effective operational management and forecasting.
Bearish Points (7)
High Price-to-Sales Ratio
The current Price/Sales (PS) ratio of 82.0 (TTM) is exceptionally high, even with the downward trend. This suggests significant market expectations for future revenue growth that may be difficult to achieve, indicating a potentially overvalued stock.
Negative Net Income and Margins
The company has consistently reported negative net income and net margins (e.g., -3374.7% in 2024Q4). This indicates ongoing losses, a critical concern for investors unless a clear path to profitability is evident.
Calendar
August 2025
4
Next Earnings Date
H: $-0.37
A: $-0.47
L: $-0.53
H: 500.00K
A: 66.67K
0Profile
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
13.90 USD
The 39 analysts offering 1 year price forecasts for RLAY have a max estimate of 29.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in precision oncology, focusing on RAS pathway inhibitors and other difficult-to-drug targets, similar to Relay's approach to protein motion and drugging challenging proteins.
Weight: 90
Direct competitor specializing in allosteric kinase inhibitors and targeting previously undruggable mutations with its MasterKey platform, analogous to Relay's platform innovation in addressing protein motion.
Weight: 88
Leverages AI and machine learning for drug discovery, sharing a similar emphasis on computational approaches to identify new therapies and drug targets, mirroring Relay's tech-driven platform.
Weight: 85
Provides a leading computational platform for drug discovery and materials science, which is a foundational technology used by many companies, including potentially Relay, for rational drug design and optimization.